Journal info (provided by editor)

% accepted last year
34% accepted
% immediately rejected last year
33% imm. rejected
Articles published last year
151 articles
Manuscripts received last year
396 manuscripts
Open access status
optional
Manuscript handling fee
none

Impact factors (provided by editor)

Two-year impact factor
4.85
Five-year impact factor
3.73

Aims and Scope

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.